Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid

NCT02339740 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02339740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02339740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 21, 2015
Completion date
June 30, 2029
Enrollment
158 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); pml-rara